Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The myelodysplastic/myeloproliferative disorders: the interface.

John M Bennett1

  • 1Department of Medicine, Pathology, and Laboratory Medicine, University of Rochester Medical Center, The James P. Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA. John_Bennett@urmc.rochester.edu

Hematology/Oncology Clinics of North America
|October 17, 2003
PubMed
Summary

Most myelodysplastic syndromes are distinct from myeloproliferative disorders, though some cases present overlapping features. Chronic myelomonocytic leukemia is now considered a composite disorder for clinical management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Unique structural and ligand-binding properties of the <i>Staphylococcus aureus</i> serine hydrolase FphE.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Unique structural and ligand binding properties of the <i>Staphylococcus aureus</i> serine hydrolase FphE.

bioRxiv : the preprint server for biology·2025
Same author

The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification.

Leukemia·2025
Same author

Chemoenzymatic Skeletal Editing of Natural Product Scaffolds via P450-Controlled Site-Selective Ring Expansion at Aliphatic C─H Sites.

Angewandte Chemie (International ed. in English)·2025
Same author

Identification of covalent inhibitors of Staphylococcus aureus serine hydrolases important for virulence and biofilm formation.

Nature communications·2025

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) are distinct myeloid malignancies.
  • Differentiating between MDS and MPD is crucial for accurate diagnosis and treatment.

Purpose of the Study:

  • To clarify the diagnostic distinctions between myelodysplastic syndromes and myeloproliferative disorders.
  • To discuss the classification and therapeutic implications of overlapping features, particularly in chronic myelomonocytic leukemia.

Main Methods:

  • Morphological analysis of bone marrow and peripheral blood smears.
  • Review of clinical and laboratory features differentiating MDS and MPD.
  • Evaluation of current classification systems for myeloid neoplasms.

Related Experiment Videos

Main Results:

  • Most cases of MDS and MPD can be readily distinguished based on distinct clinical and morphological criteria.
  • A subset of patients exhibits overlapping features, including morphologic dysplasia and evidence of myeloid proliferation.
  • Chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), and juvenile myelomonocytic leukemia (JMML) are recognized as entities with composite features.

Conclusions:

  • Accurate differentiation of MDS and MPD is generally achievable.
  • Overlapping features necessitate careful evaluation for specific diagnoses like CMML.
  • Current understanding views CMML as a composite disorder, impacting therapeutic strategies.